Abstract

Establishing a wide therapeutic index (TI) for pre-clinical safety is important during lead optimization (LO) in research, prior to clinical development, although is often limited by a molecules physiochemical characteristics. Recent advances in the application of the innovative vibrating mesh spray-drying technology to prepare amorphous solid dispersions may offer an opportunity to achieve high plasma concentrations of poorly soluble NCEs to enable testing and establishment of a wide TI in safety pharmacology studies. While some of the amorphous solid dispersion carriers are generally recognized as safe for clinical use, whether they are sufficiently benign to enable in vivo pharmacology studies has not been sufficiently demonstrated. Thus, the physical properties, and effect in a battery of in vivo safety pharmacology models, were assessed in three classes of polymers employed as spray-dried dispersion carriers. The polymers (HPMC-AS, Eudragit, PVAP) displayed low affinity with acetone/methanol, suitable for solvent-based spray drying. The water sorption of the polymers was moderate, and the degree of hysteresis of HPMC-AS was smaller than Eudragit and PVAP indicating the intermolecular interaction of water-cellulose molecules is weaker than water-acrylate or water-polyvinyl molecules. The polymer particles were well-suspended without aggregation with a mean particle size less than 3 μm in an aqueous vehicle. When tested in conscious Wistar Han rats in safety pharmacology models (n = 6–8/dose/polymer) investigating effects on CNS, gastrointestinal, and cardiovascular function, no liabilities were identified at any dose tested (30–300 mg/kg PO, suspension). In brief, the polymers had no effect in a modified Irwin test that included observational and evoked endpoints related to stereotypies, excitation, sedation, pain/anesthesia, autonomic balance, reflexes, and others. No effect of the polymers on gastric emptying or intestinal transit was observed when measured using a barium sulfate tracer material. Finally, in telemetry-instrumented rats the polymers had no effect on acute or 24-h mean blood pressure and heart rate values at doses up to 300 mg/kg. Thus, the properties of the three enteric polymers are appropriate as spray-dried dispersion carriers and were benign in a battery of safety pharmacology studies, demonstrating their applicability to enable in vivo safety pharmacology profiling of poorly soluble molecules during LO.

Highlights

  • Safety pharmacology studies in drug discovery are often performed during compound selection in lead optimization, prior to entry into long-term dose-escalation studies (Hamdam et al, 2013)

  • We evaluated three enteric polymers from three distinct classes and with different structures that are commonly used as amorphous solid dispersion carriers including cellulose-based hydroxypropylmethylcellulose acetate succinateLF (HPMC-AS), acrylate-based EUDRAGIT L100-55 (Eudragit), and polyvinyl-based polyvinyl acetate phthalate (PVAP)

  • Based on the aforementioned properties and tolerability of specific polymers (HPMC-AS, Eudragit, and PVAP) representing three classes, we demonstrate that all are amenable as carriers for spray-dried dispersions with appropriate physiochemical properties and, importantly, none of the enteric polymers had any effect on CNS, gastrointestinal, or cardiovascular functional parameters when tested at high doses in rats

Read more

Summary

Introduction

Safety pharmacology studies in drug discovery are often performed during compound selection in lead optimization, prior to entry into long-term dose-escalation studies (Hamdam et al, 2013). Effects on other organ systems (e.g., gastrointestinal and renal function) are commonly assessed as part of a comprehensive battery of in vivo safety profiling (Al-Saffar et al, 2015; Benjamin et al, 2015). While establishing a wide therapeutic index (TI) in these models is important prior to advancement of new chemical entities (NCEs) into clinical development, molecules are often encountered with poor aqueous solubility and dissolution characteristics, and a poor pharmacokinetic profile that limits the ability to achieve high plasma levels after oral administration. To establish a wide TI for poorly soluble molecules the use of enabling formulations is essential (Li and Zhao, 2007) and whereby the formulation does not interfere with the primary safety endpoints being measured. Excipient tolerance can be impacted by the fasted/fed state of the animal who may become less tolerant of excipients as their plane of nutrition decreases (Li and Zhao, 2007)

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.